Personalized chemotherapy selection for breast cancer using gene expression profiles.

Sci Rep · 2017 · PMC5335706 · PMID 28256629

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

When compared to the regimen with the highest pCR, the improvement was also significant for HER2-negative patients (30.6% from TxA regimen), and highly significant for HER2-negative and ER-negative patients (41.8% from TxA regimen).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.